After more than 17 months without a meeting, the U.S. Preventive Services Task Force has new members. That’s good news. Its recommendations shape preventive care for millions of Americans, and the backlog of topics waiting for a decision has only grown while the panel sat idle.
But who was appointed, and how, matters. And today’s announcement leaves a lot unanswered.
Start with the composition. Five of the eight new members are specialists: pediatric hematology-oncology, cardiology, gastroenterology, radiology. The panel also gains a pediatrician, a family physician, and a health economist. None of that is disqualifying.
Specialists have always contributed to the Task Force’s evidence reviews, and they should. But the Task Force's job is unusually broad. It weighs evidence across the full range of clinical preventive services, for every age group, and it has historically drawn on people trained in primary care, prevention, and evidence-based medicine. The question is whether this panel, as constituted, has the breadth to do the whole job.
Then there’s process. The public should be able to see how the new members were chosen and vetted. The Task Force has established procedures for disclosing and managing conflicts of interest. Those disclosures, and the process used to evaluate them, should be public. A body whose recommendations affect care for millions of people is only as independent as the process that selected it and oversees it.
Finally, methodology. HHS singled out one new member’s expertise in evaluating the cost and value of health care services. That's a notable thing to highlight, because the Task Force has never included cost in its recommendation grades. Those grades are based on benefits and harms. Nothing else. If the administration intends to change that, the public deserves to know, and any change should be transparent and grounded in law and evidence.
New members alone can’t fix the Task Force
None of this should distract from the larger problem. The evidence infrastructure the Task Force depends on has been badly damaged too.
The Task Force evaluates evidence. It doesn't produce it. Its recommendations rest on systematic reviews and scientific support that come through the federal evidence infrastructure, and AHRQ is the agency that provides that support: scientific, technical, administrative, and dissemination, including coordinating the evidence reports themselves. (ahrq.gov)
AHRQ has lost a large share of its staff and cancelled more than 150 research grants, including grants that feed the nation’s health evidence base. Appointing new members doesn't undo any of that. The best-qualified panel in the world still needs rigorous, current evidence to evaluate. Without it, there's nothing to grade.
That matters because the Task Force’s recommendations are how clinicians and patients decide which preventive services offer enough benefit to be worth the harms. Screening, counseling, preventive medications, across the lifespan.
The Task Force also has a statutory duty to identify gaps in the evidence and report research priorities to Congress. That’s a feedback loop. Research produces evidence. Evidence reviews inform recommendations. The Task Force flags what remains unknown, and those gaps point future research where it's needed.
Break any link in that chain, and the damage doesn’t stop with today's recommendations.
We’ll be watching closely as the reconstituted Task Force gets to work. Congress and HHS should be asking not just who is on the Task Force, but whether the scientific infrastructure behind it is strong enough to let it do its job independently and rigorously.
The country needs both: a Task Force with the breadth and independence to evaluate preventive care, and an evidence system capable of giving it the science that work requires.